Last updated: 11/03/2018 21:50:49
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study.
Evaluation of Secondary Malignancies in Patients Treated with Dabrafenib in Randomized, Controlled Trials
GSK study ID
201710
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: Evaluation of Secondary Malignancies in Patients Treated with Dabrafenib in Randomized, Controlled Trials
Trial description: An FDA post-marketing requirement (PMR) to further characterize secondary malignancies in subjects treated with dabrafenib, either as monotherapy or in combination with other anti-cancer therapies on randomized controlled clinical trials. (TAFINLAR® is a trademark of the GlaxoSmithKline group of companies)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Safety
Timeframe: time varied through 2020
Secondary outcomes:
None
Timeframe: NA
Interventions:
Other: Not Applicable
Enrollment:
Not applicable
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Other
Clinical publications:
Not applicable
Medical condition
Melanoma
Product
dabrafenib
Collaborators
Not applicable
Study date(s)
September 2013 to October 2020
Type
Observational
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
- subjects treated with dabrafenib, either as monotherapy or in combination with other anti-cancer therapies on randomized controlled clinical trials
- Data from the following phase III randomized studies will be integrated: BRF113683 (BREAK-3), MEK115306 (COMBI-D), MEK116513 (COMBI-V), BRF115532 (COMBI-AD)
- None
Inclusion and exclusion criteria
Inclusion criteria:
- subjects treated with dabrafenib, either as monotherapy or in combination with other anti-cancer therapies on randomized controlled clinical trials
- Data from the following phase III randomized studies will be integrated: BRF113683 (BREAK-3), MEK115306 (COMBI-D), MEK116513 (COMBI-V), BRF115532 (COMBI-AD)
- Any additional GSK sponsored randomized study of dabrafenib either as monotherapy or in combination with other anti-cancer agents which reaches the primary analysis endpoint during the reporting time period for each interim and final report will also be integrated
- All analyses will use the Safety population (SAFETY) for each study, which comprises all randomized subjects who received at least one dose of study medication and will be based on the actual treatment received if this differed from that to which the subject was randomized
- As the trials are reported, the treatment arms to be used in analyses are as follows:
- Dabrafenib monotherapy (BREAK-3 + COMBI-D);
- MEK + Dabrafenib (COMBI-D+COMBI-V+COMBI-AD);
- DTIC (BREAK-3);
- Vemurafenib (COMBI-V); and
- Placebo (COMBI-AD)
Exclusion criteria:
- None
Trial location(s)
No location data available.
Study documents
No study documents available.
Results overview
No study documents available
Recruitment status
No longer a GSK study
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website